Where sCD14 is reported
Also listed as: Monocyte activation; Monocyte activation marker; Monocyte activation — LC overlap; Soluble CD14 (sCD14)
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| Gulf War Illness | ↑ elevated | healthy Gulf War veteran controls | Innate immune activation | Gean et al. 2021 |
| Long COVID | ↑ elevated | healthy controls, recovered individuals without persistent symptoms | Innate immune activation | Saito et al. 2024 |
| ME/CFS | ↑ elevated | healthy controls | Innate immune activation | Saito et al. 2024 |
Frequently asked questions
In which conditions is sCD14 altered?
In the OSMF atlas sCD14 is reported in Gulf War Illness, Long COVID, ME/CFS. It is elevated in 3 across 3 entries.
Does sCD14 point to one specific diagnosis?
No. Because sCD14 changes in several conditions (Gulf War Illness, Long COVID, ME/CFS), an abnormal result cannot identify which condition, if any, is present. It must be interpreted with symptoms, history and other tests.
Is there a standard clinical test for sCD14?
The atlas entries for sCD14 do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.
Is one abnormal sCD14 result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.